Oculis (NASDAQ:OCS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oculis (NASDAQ:OCS) from a strong sell rating to a sell rating in a research note issued to investors on Saturday.

OCS has been the subject of a number of other research reports. JPMorgan Chase & Co. cut their target price on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Robert W. Baird lowered their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a report on Monday, June 1st. Needham & Company LLC dropped their price target on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Oculis in a report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Oculis presently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Price Performance

OCS opened at $12.76 on Friday. The company’s 50-day simple moving average is $12.13 and its two-hundred day simple moving average is $22.19. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The stock has a market capitalization of $739.82 million, a P/E ratio of -7.33 and a beta of 0.51. Oculis has a 52-week low of $10.52 and a 52-week high of $34.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The company had revenue of $0.38 million during the quarter. As a group, analysts predict that Oculis will post -2.22 EPS for the current year.

Institutional Trading of Oculis

Several large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its position in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the period. Koshinski Asset Management Inc. bought a new stake in shares of Oculis during the 1st quarter valued at $238,000. Millennium Management LLC purchased a new stake in shares of Oculis in the 4th quarter worth $312,000. Himension Capital Singapore PTE. LTD. purchased a new stake in shares of Oculis in the 1st quarter worth $503,000. Finally, Marshall Wace LLP bought a new position in Oculis in the 2nd quarter worth $393,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.